Fundsmith Reduces $19M in Doximity, Inc. ($DOCS)
Key Points
- Fundsmith changed its Doximity, Inc. ($DOCS) stake by 58.1% last quarter, cutting to 691,786 shares worth $13.86 million.
- Wall Street's consensus rating on $DOCS is Buy and an average price target of $25.42.
- $DOCS last traded around $20.04.
Fundsmith reduced its position in Doximity, Inc. ($DOCS) by 58.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 691,786 shares of Doximity, Inc. after selling 958,216 shares during the quarter. Fundsmith's holdings in Doximity, Inc. were worth $13.86 million as of its most recent filing.
Doximity, Inc. ($DOCS) Stock
Doximity, Inc. Earnings
Analysts Set New Price Targets
About Doximity, Inc.
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.